[go: up one dir, main page]

MXPA03011705A - Antihistamines for the treatment of nasal congestion and nasal obstruction. - Google Patents

Antihistamines for the treatment of nasal congestion and nasal obstruction.

Info

Publication number
MXPA03011705A
MXPA03011705A MXPA03011705A MXPA03011705A MXPA03011705A MX PA03011705 A MXPA03011705 A MX PA03011705A MX PA03011705 A MXPA03011705 A MX PA03011705A MX PA03011705 A MXPA03011705 A MX PA03011705A MX PA03011705 A MXPA03011705 A MX PA03011705A
Authority
MX
Mexico
Prior art keywords
nasal
antihistamines
treatment
congestion
obstruction
Prior art date
Application number
MXPA03011705A
Other languages
Spanish (es)
Inventor
M Salmun Luis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA03011705A publication Critical patent/MXPA03011705A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The use of desloratadine and/or other antihistamines for treating and/or preventing severe nasal congestion and/or nasal blockage associated with allergic and inflammatory conditions of the upper and lower airway passages in a human.
MXPA03011705A 2001-06-20 2002-06-19 Antihistamines for the treatment of nasal congestion and nasal obstruction. MXPA03011705A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29963601P 2001-06-20 2001-06-20
US29963701P 2001-06-20 2001-06-20
PCT/US2002/019414 WO2003000264A1 (en) 2001-06-20 2002-06-19 Antihistamines for the treatment of nasal congestion and nasal obstruction

Publications (1)

Publication Number Publication Date
MXPA03011705A true MXPA03011705A (en) 2004-03-19

Family

ID=26971322

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011705A MXPA03011705A (en) 2001-06-20 2002-06-19 Antihistamines for the treatment of nasal congestion and nasal obstruction.

Country Status (9)

Country Link
EP (1) EP1401444A1 (en)
JP (1) JP2004534820A (en)
CN (1) CN1518448A (en)
BR (1) BR0210534A (en)
CA (1) CA2450583A1 (en)
HU (1) HUP0401630A2 (en)
MX (1) MXPA03011705A (en)
NO (1) NO20035706D0 (en)
WO (1) WO2003000264A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105760A1 (en) * 2003-05-28 2004-12-09 Ucb Farchim, S.A. Use of efletirizine for treating persistent allergic rhinitis
CN100444841C (en) * 2004-11-10 2008-12-24 鲁南制药集团股份有限公司 Externally used loratadine formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
ES2210957T3 (en) * 1992-09-03 2004-07-01 Sepracor Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING NORASTEMIZOL.
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
EP0719156A1 (en) * 1993-09-07 1996-07-03 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
HUP9904075A3 (en) * 1996-10-31 2002-02-28 Schering Corp Composition, for the treatment of asthma,containing loratadine and a decongestant
CA2304005A1 (en) * 1997-09-19 1999-04-01 The Procter & Gamble Company Compositions and methods for treating respiratory disorders
CN1283115A (en) * 1997-12-23 2001-02-07 先灵公司 Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6248308B1 (en) * 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6495529B1 (en) * 1998-07-01 2002-12-17 Warner-Lambert Company (−)-Pseudoephedrine as a sympathomimetic drug
CN1161112C (en) * 1999-02-23 2004-08-11 株式会社柳韩洋行 Pharmaceutical capsule composition containing loratadine and pseudoephedrine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
SK287684B6 (en) * 1999-12-20 2011-06-06 Schering Corporation Sustained release solid oral pharmaceutical dosage composition
JP2003521515A (en) * 2000-02-03 2003-07-15 シェーリング コーポレイション Treatment of allergic and inflammatory conditions
PE20020324A1 (en) * 2000-10-06 2002-06-18 Boehringer Ingelheim Int NEW PHARMACEUTICAL COMPOSITIONS CONTAINING EPINASTIN AND PSEUDOEPHEDRINE

Also Published As

Publication number Publication date
WO2003000264A1 (en) 2003-01-03
HUP0401630A2 (en) 2004-12-28
JP2004534820A (en) 2004-11-18
CN1518448A (en) 2004-08-04
CA2450583A1 (en) 2003-01-03
EP1401444A1 (en) 2004-03-31
BR0210534A (en) 2004-06-22
NO20035706D0 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
HUP0203529A2 (en) Treating sleep disorders using desloratadine
EP1416885A4 (en) Methods and devices for delivery of therapeutic capable agents with variable release profile
NO20033446D0 (en) Medication for the treatment of osteonecrosis and for the care of people at risk of developing osteonecrosis
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
NZ544719A (en) Combination of mGluR2 antagonist and aChE inhibitor for treatment of acute and/or chronic neurological disorders
NO994165D0 (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
IS6967A (en) New cyano-linked dihydropyrimidine compounds and their use in the treatment of diseases
EE200300363A (en) Use of N- (Pyridinyl) -1H-Indole-1-Amine Compounds in the manufacture of a medicament for the treatment of diseases and conditions associated with myelin loss
MY122838A (en) Treating allergic and inflammatory conditions
MXPA05001885A (en) The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis.
PL366640A1 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158703A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
GB0128674D0 (en) Treatment of sleep disorders and the like
MXPA03011705A (en) Antihistamines for the treatment of nasal congestion and nasal obstruction.
IL158632A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
IL158695A0 (en) 4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2002328884A1 (en) Use of trifluoroacetyl alkyl-substituted phenyl derivatives, phenol derivatives and benzoyl derivatives in the treatment and/or prophylaxis of obesity and accompanying diseases and/or secondary diseases
NO20043614L (en) 2'-halogen-3 ', 5'-dialkoxyphen-1'-yl-imino-2-imidazolidine in-derivatives and their use in the treatment of urinary incontinence
WO2002067938A3 (en) Treating or reducing the risk of cardiovascular disease
AU2002365878A8 (en) Devices and methods for delivery of medically appropriate fluids
WO2001021161A3 (en) Use of desloratadine for treating allergic and inflammatory conditions
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
ZA200309766B (en) Antihistamines for the treatment of nasal congestion and nasal obstruction.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal